A detailed history of Nuveen Asset Management, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 227,032 shares of SUPN stock, worth $5.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
227,032
Previous 130,731 73.66%
Holding current value
$5.85 Million
Previous $3.78 Million 104.71%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$27.11 - $35.17 $2.61 Million - $3.39 Million
96,301 Added 73.66%
227,032 $7.74 Million
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $2.27 Million - $2.96 Million
-99,861 Reduced 43.31%
130,731 $3.78 Million
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $1.59 Million - $1.9 Million
-57,714 Reduced 20.02%
230,592 $6.36 Million
Q2 2023

Aug 14, 2023

SELL
$29.91 - $38.73 $4.15 Million - $5.37 Million
-138,674 Reduced 32.48%
288,306 $8.67 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $282,409 - $339,812
8,085 Added 1.93%
426,980 $15.5 Million
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $1.41 Million - $1.72 Million
45,386 Added 12.15%
418,895 $14.9 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $545,570 - $671,019
18,950 Added 5.34%
373,509 $12.6 Million
Q2 2022

Aug 15, 2022

SELL
$25.33 - $34.25 $4.05 Million - $5.47 Million
-159,833 Reduced 31.07%
354,559 $10.3 Million
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $6.91 Million - $7.97 Million
-242,239 Reduced 32.02%
514,392 $16 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $5,247 - $6,809
199 Added 0.03%
756,631 $21.1 Million
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $6.84 Million - $9.11 Million
290,359 Added 62.3%
756,432 $20.6 Million
Q2 2021

Aug 16, 2021

BUY
$26.72 - $33.19 $4.62 Million - $5.74 Million
172,875 Added 58.96%
466,073 $14.4 Million
Q1 2021

May 17, 2021

BUY
$24.15 - $31.45 $19,899 - $25,914
824 Added 0.28%
293,198 $7.68 Million
Q4 2020

Feb 16, 2021

SELL
$17.7 - $25.81 $76,393 - $111,395
-4,316 Reduced 1.45%
292,374 $7.36 Million
Q3 2020

Nov 16, 2020

SELL
$20.2 - $25.05 $648,561 - $804,280
-32,107 Reduced 9.76%
296,690 $6.18 Million
Q2 2020

Aug 14, 2020

BUY
$17.09 - $24.89 $221,195 - $322,151
12,943 Added 4.1%
328,797 $7.81 Million
Q1 2020

May 14, 2020

BUY
$14.45 - $24.69 $237,427 - $405,681
16,431 Added 5.49%
315,854 $5.68 Million
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $6.68 Million - $9.76 Million
-335,068 Reduced 52.81%
299,423 $7.1 Million
Q3 2019

Nov 14, 2019

BUY
$25.47 - $33.37 $8.25 Million - $10.8 Million
323,879 Added 104.27%
634,491 $17.4 Million
Q2 2019

Aug 15, 2019

BUY
$29.96 - $38.87 $8.95 Million - $11.6 Million
298,624 Added 2491.02%
310,612 $10.3 Million
Q1 2019

May 14, 2019

BUY
$32.77 - $41.99 $141,533 - $181,354
4,319 Added 56.32%
11,988 $420,000
Q4 2018

Feb 14, 2019

SELL
$30.84 - $49.51 $178,748 - $286,959
-5,796 Reduced 43.04%
7,669 $255,000
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $640,457 - $848,193
-14,999 Reduced 52.69%
13,465 $678,000
Q2 2018

Aug 14, 2018

BUY
$44.1 - $59.85 $310,949 - $422,002
7,051 Added 32.93%
28,464 $1.7 Million
Q1 2018

May 14, 2018

BUY
$37.15 - $46.9 $795,492 - $1 Million
21,413 New
21,413 $981,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.38B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.